Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA approves Vumerity for the treatment of multiple sclerosis

Oct. 31, 2019

First patient dosed in phase II study of novel hepcidin mimetic PTG-300

Oct. 31, 2019

Shandong Luoxin Pharmacy Group and Luoxin Pharmaceutical (Shanghai) patent TLR7 agonists

Oct. 31, 2019

Bayer Pharma describes new kallikrein B inhibitors

Oct. 31, 2019

Cyclin-dependant kinase 7 inhibitors discovered by Lead Discovery Center and Qurient

Oct. 31, 2019

Preclinical evaluation of highly potent caspase-cleavable docetaxel prodrug, MPD-03

Oct. 31, 2019

INTH-454: A small molecule modulator of the p300/CBP interactome for cancer

Oct. 31, 2019

(R)-[18F]MH.MZ as a novel PET tracer for the detection of 5-HT2A receptors in the human brain

Oct. 31, 2019

Topline results presented from phase III CMS-001 study of amifampridine phosphate

Oct. 31, 2019

Cyclerion Therapeutics presents topline data from two phase II studies of praliciguat

Oct. 31, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...